Project Grant R42AI131784

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Qrono, Inc., a for-profit medical research and development company. The grant funding supports the development of QR402, a first-in-class, oral nanomedicine that uses an AMPK pathway agonist to target intestinal dendritic cells and restore immunological tolerance as a preventative therapy for type 1 diabetes. The goal is to...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $601,340 to Transchromix LLC to develop a novel therapeutic intervention for early-stage type 1 diabetes (T1D). The research aims to target a translational regulatory mechanism involving the G9A histone methyltransferase, which was found to specifically suppress the pathogenicity of...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) totaling $215,128.00 supports research to study the role and origin of hybrid insulin peptides in the pathogenesis of type 1 diabetes. The key research objectives include: Assessing the formation of cathepsin D-mediated hybrid insulin peptides (HIPs) and their impact on disease progression in a mouse model of type 1...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,592,670 to the University of Massachusetts Medical School (UMass Medical) to support research on the influence of MHC-II polymorphisms on autoimmune T cell repertoire development and function in type 1 diabetes (T1D). The award period runs from July 15, 2024 to June 30, 2029. The...

This $3,227,113 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to investigate the mechanisms by which CD4+ T cells contribute to the development of type 1 diabetes. The University of Pennsylvania will lead this 3-year research project to define the cross-reactivity between microbial and self-antigens that may enable autoreactive T...

This Project Grant award, provided by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), focuses on investigating the role of lymph node stromal cells in maintaining peripheral tolerance and reducing autoimmunity in type 1 diabetes. The primary awardee, The Trustees of Columbia University in the City of New York, will receive $602,531 to conduct research aimed at: Evaluating...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to identify additional autoantibodies against adipocyte-expressed proteins that cause acquired lipodystrophies (AGL and APL) and determine their function in adipocyte biology. The $673,344 award to The University of Texas Southwestern Medical Center will also investigate the autoimmune...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,998 to support the development of advanced stem cell-derived pancreatic islet cell technologies for type 1 diabetes treatment. The key products and services to be delivered include: Assessing the impact of genetically modifying stem cell-derived islet cells to be more resilient to...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $875,714 to the University of Washington to develop and validate a toolbox of AI-designed mini-proteins (epibinders) that can drive more efficient differentiation of pluripotent stem cells into functional pancreatic islet tissue. The goal is to enhance the therapeutic potential of stem...